Artax Biopharma

Executive Summary

Artax Biopharma is a private, Phase 2 clinical-stage biotechnology company based in Cambridge, MA, developing first-in-class oral small molecule Nck modulators for autoimmune diseases. Its lead candidate, AX-158, targets T cell activation at Signal 1 to restore immune balance without broad immunosuppression. The company has reported promising biomarker and clinical data from its Phase 2a psoriasis trial, suggesting potential for disease-modifying activity with a favorable safety profile. If successful, AX-158 could offer a novel therapeutic option for psoriasis and other T cell-mediated autoimmune conditions, addressing a significant unmet need.

Upcoming Catalysts (preview)

• H2 2026Phase 2a psoriasis trial top-line data65% success
• 2026Strategic partnership for AX-15845% success
• 2026Series C financing round75% success